Heparin and Heparan Sulfate: Analyzing Structure and Microheterogeneity

Overview

Journal Handb Exp Pharmacol

Specialty Pharmacology

Date 2012 May 9

PMID 22566225

Citations 69

Authors

Zachary Shriver

Ishan Capila

Ganesh Venkataraman

Ram Sasisekharan

Affiliations

Soon will be listed here.

Abstract

The structural microheterogeneity of heparin and heparan sulfate is one of the major reasons for the multifunctionality exhibited by this class of molecules. In a physiological context, these molecules primarily exert their effects extracellularly by mediating key processes of cellular cross-talk and signaling leading to the modulation of a number of different biological activities including development, cell proliferation, and inflammation. This structural diversity is biosynthetically imprinted in a nontemplate-driven manner and may also be dynamically remodeled as cellular function changes. Understanding the structural information encoded in these molecules forms the basis for attempting to understand the complex biology they mediate. This chapter provides an overview of the origin of the structural microheterogeneity observed in heparin and heparan sulfate, and the orthogonal analytical methodologies that are required to help decipher this information.

Citing Articles

Extracorporeal therapies in sepsis: a comprehensive review of the Selective Cytopheretic Device, Polymyxin B and Seraph cartridges.

Yessayan L, Pino C, Humes H Ren Fail. 2025; 47(1):2459349.

PMID: 39962644 PMC: 11837919. DOI: 10.1080/0886022X.2025.2459349.

Synthesis and Characterization of Glycosaminoglycan Mimetic Variants to Promote Chondrogenesis.

Vincent R, Foston M, Hammond W, Collins G, Arinzeh T ACS Omega. 2025; 10(5):4505-4515.

PMID: 39959109 PMC: 11822690. DOI: 10.1021/acsomega.4c08084.

Mapping the FGF2 Interactome Identifies a Functional Proteoglycan Coreceptor.

Critcher M, Pang J, Huang M ACS Chem Biol. 2024; 20(1):105-116.

PMID: 39704408 PMC: 11858877. DOI: 10.1021/acschembio.4c00475.

Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy.

Shishido S, Suresh D, Courcoubetis G, Ye B, Lin E, Mason J BJC Rep. 2024; 2(1):47.

PMID: 39516545 PMC: 11524105. DOI: 10.1038/s44276-024-00069-3.

Extracellular Matrix Components and Mechanosensing Pathways in Health and Disease.

Berdiaki A, Neagu M, Tzanakakis P, Spyridaki I, Perez S, Nikitovic D Biomolecules. 2024; 14(9).

PMID: 39334952 PMC: 11430160. DOI: 10.3390/biom14091186.

References

Shukla D, Liu J, Blaiklock P, Shworak N, Bai X, Esko J . A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999; 99(1):13-22. DOI: 10.1016/s0092-8674(00)80058-6. View

Sanderson P, Huckerby T, Nieduszynski I . Conformational equilibria of alpha-L-iduronate residues in disaccharides derived from heparin. Biochem J. 1987; 243(1):175-81. PMC: 1147829. DOI: 10.1042/bj2430175. View

Casu B, Guerrini M, Naggi A, Torri G, Boveri G, Gonella S . Differentiation of beef and pig mucosal heparins by NMR spectroscopy. Thromb Haemost. 1995; 74(4):1205. View

Rosenberg R, Lam L . Correlation between structure and function of heparin. Proc Natl Acad Sci U S A. 1979; 76(3):1218-22. PMC: 383221. DOI: 10.1073/pnas.76.3.1218. View

Guerrini M, Raman R, Venkataraman G, Torri G, Sasisekharan R, Casu B . A novel computational approach to integrate NMR spectroscopy and capillary electrophoresis for structure assignment of heparin and heparan sulfate oligosaccharides. Glycobiology. 2002; 12(11):713-9. DOI: 10.1093/glycob/cwf084. View

Liu J, Shriver Z, Pope R, Thorp S, Duncan M, Copeland R . Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem. 2002; 277(36):33456-67. DOI: 10.1074/jbc.M202034200. View

Shi X, Zaia J . Organ-specific heparan sulfate structural phenotypes. J Biol Chem. 2009; 284(18):11806-14. PMC: 2673249. DOI: 10.1074/jbc.M809637200. View

Saad O, Leary J . Compositional analysis and quantification of heparin and heparan sulfate by electrospray ionization ion trap mass spectrometry. Anal Chem. 2003; 75(13):2985-95. DOI: 10.1021/ac0340455. View

Sugahara K, Kitagawa H . Heparin and heparan sulfate biosynthesis. IUBMB Life. 2003; 54(4):163-75. DOI: 10.1080/15216540214928. View

10.

Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G . Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 2007; 33(5):478-87. DOI: 10.1055/s-2007-982078. View

11.

Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A . Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008; 26(6):669-75. PMC: 3491566. DOI: 10.1038/nbt1407. View

12.

Linhardt R, Loganathan D, Al-Hakim A, Wang H, Walenga J, Hoppensteadt D . Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J Med Chem. 1990; 33(6):1639-45. DOI: 10.1021/jm00168a017. View

13.

Ferro D, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V . Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res. 1990; 195(2):157-67. DOI: 10.1016/0008-6215(90)84164-p. View

14.

Linhardt R, Gunay N . Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999; 25 Suppl 3:5-16. View

15.

Liu R, Xu Y, Chen M, Weiwer M, Zhou X, Bridges A . Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem. 2010; 285(44):34240-9. PMC: 2962522. DOI: 10.1074/jbc.M110.159152. View

16.

Linhardt R, Rice K, Kim Y, Lohse D, Wang H, Loganathan D . Mapping and quantification of the major oligosaccharide components of heparin. Biochem J. 1988; 254(3):781-7. PMC: 1135151. DOI: 10.1042/bj2540781. View

17.

Faham S, Hileman R, Fromm J, Linhardt R, Rees D . Heparin structure and interactions with basic fibroblast growth factor. Science. 1996; 271(5252):1116-20. DOI: 10.1126/science.271.5252.1116. View

18.

Guerrini M, Bisio A, Torri G . Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost. 2001; 27(5):473-82. DOI: 10.1055/s-2001-17958. View

19.

Karamanos N, Vanky P, Tzanakakis G, Tsegenidis T, Hjerpe A . Ion-pair high-performance liquid chromatography for determining disaccharide composition in heparin and heparan sulphate. J Chromatogr A. 1997; 765(2):169-79. DOI: 10.1016/s0021-9673(96)00930-2. View

20.

Kuberan B, Beeler D, Lech M, Wu Z, Rosenberg R . Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem. 2003; 278(52):52613-21. DOI: 10.1074/jbc.M305029200. View